- World Pharma News Home » Clinical Trials » Lapatinib (Tykerb/Tyverb) to be investigated in landmark early breast cancer trial
(a free service delivered by FeedBurner)
GlaxoSmithKline (GSK), in collaboration with the Breast International Group (BIG), a leading academic breast cancer research network, and one of its member groups, the Spanish Breast Cancer Cooperative Group (SOLTI), announced the start of a global Phase III study that will examine the role of lapatinib (Tykerb®/Tyverb®)in the treatment of early breast cancer (EBC). Neo-ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) will evaluate and compare the rate at which cancer cells disappear in the breast following treatment with lapatinib and/or trastuzumab before surgery in women with early-stage ErbB2-positive (HER2-positive) positive breast cancer. This type of treatment is referred to as neo-adjuvant therapy. Lapatinib is an investigational drug and has not yet been approved for this indication.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments